儿童耐药性的总后方象限断开连接
1Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.
Epilepsia open
|September 19, 2024
概括
整体后方象限切断 (PQD) 手术在70.5%的儿科患者中有效控制了抗药性发作. 手术后的结果是有利的,没有死亡或严重的并发症,并注意到发育的改善.
科学领域:
- 儿科神经外科 儿科神经外科
- 手术 手术 手术
- 发育神经科学的发展神经科学.
背景情况:
- 儿童的耐药性 (DRE) 对神经发育和生活质量构成重大挑战.
- 对于具有结构异常的难以治疗的DRE,可以考虑像后方象限断开 (PQD) 这样的手术干预.
- 关于儿童群体中总PQD的疗效和发育影响的数据有限.
研究的目的:
- 为了评估DRE儿童的总PQD之后的发作结果.
- 确定影响控制和手术后发育轨迹的预后因素.
- 为了评估PQD整体手术后发育水平的变化.
主要方法:
- 来自61名儿童患者的临床数据的回顾性分析,这些患者接受了DRE的总PQD.
- 使用恩格尔分类对扣押结果的评估.
- 使用格里菲斯精神发展尺度-中国 (GMDS-C) 评估发育变化.手术前后.
- 对手术前数据,手术因素和发育结果的相关性分析.
主要成果:
- 70.5%的儿科患者在术后实现了无发作.
- 单变量和多变量分析确定了电脑电图 (EEG) 和急性术后 (APOS) 作为预后的重要预测因素.
- 在术前发育水平和特征 (持续时间,频率,EEG,FDG-PET) 之间发现了显著的相关性.
- 手术后的GMDS-C得分有所改善,而发育系数保持稳定.
结论:
- 整体PQD手术是儿童DRE的有效治疗方法,具有结构后象限异常,可以控制发作而不会导致神经系统恶化.
- 间节脑电图异常和APOS是重要的预后指标,但不是对手术的绝对禁忌.
- 彻底的手术前评估和及时的手术干预对于优化儿科手术的结果至关重要.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.6K
09:32Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
Published on: December 18, 2016
12.3K
相关概念视频
01:24Arteries of the Lower Limbs
181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341
01:20Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
01:17Antiepileptic Drugs: Calcium Channel Blockers
341
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
341
01:14Antiepileptic Drugs: Glutamate Antagonists
292
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
292
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266